Overview

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the feasibility and efficacy of using the demethylating agent 5-Azacytidine prior to allogeneic stem cell transplantation in patients with high risk myelodysplastic syndrome (MDS).

Phase:

Phase 2

Details

Lead Sponsor:

Virginia Commonwealth University

Collaborator:

Celgene Corporation

Treatments:

Azacitidine